Background & Aim Under the regulation of various oncogenic pathways, cancer cells
undergo adaptive metabolic programming to maintain specific metabolic states that support
their uncontrolled proliferation. As it has been difficult to directly and effectively inhibit
oncogenic signaling cascades with pharmaceutical compounds, focusing on the
downstream metabolic pathways that enable indefinite growth may provide therapeutic
opportunities. Thus, we sought to characterize metabolic changes in hepatocellular …